This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	CXC chemokine receptor 2 (CXCR2; IL8RB); lymphocyte antigen 6 complex locus G (LY6G; GR1)	<p>Mouse and cell culture studies suggest blocking recruitment of GR1⁺ myeloid cells to tumors could help prevent chemotherapy resistance. GR1 is a marker of inflammatory monocytes. In multiple mouse models of cancer, infiltration of GR1⁺ myeloid cells into tumors prevented cancer cell senescence. In a chemotherapy-treated mouse model of cancer, depletion of GR1⁺ myeloid cells with a CXCR2 antagonist increased chemotherapy-induced senescence and decreased tumor size compared with no depletion. Next steps include identifying compounds that could block recruitment of GR1⁺ myeloid cells to tumors and evaluating them in combination with chemotherapy or targeted therapies.</p> <p>SciBX 7(37); doi:10.1038/scibx.2014.1096 Published online Sept. 25, 2014</p>	Patent and licensing status undisclosed	<p>Di Mitri, D. <i>et al. Nature</i>; published online Aug. 24, 2014; doi:10.1038/nature13638 Contact: Andrea Alimonti, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland e-mail: andrea.alimonti@ior.iosl.ch</p>